Pommier Y - Search Results

1

Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines.

Jandu H, Aluzaite K, Fogh L, Thrane SW, Noer JB, Proszek J, Do KN, Hansen SN, Damsgaard B, Nielsen SL, Stougaard M, Knudsen BR, Moreira J, Hamerlik P, Gajjar M, Smid M, Martens J, Foekens J, Pommier Y, Brünner N, Schrohl AS, Stenvang J. Jandu H, et al. Among authors: pommier y. BMC Cancer. 2016 Jan 22;16:34. doi: 10.1186/s12885-016-2071-1. BMC Cancer. 2016. PMID: 26801902 Free PMC article.

2

Topoisomerase I alteration in a camptothecin-resistant cell line derived from Chinese hamster DC3F cells in culture.

Tanizawa A, Pommier Y. Tanizawa A, et al. Among authors: pommier y. Cancer Res. 1992 Apr 1;52(7):1848-54. Cancer Res. 1992. PMID: 1312902

3

S-phase population analysis does not correlate with the cytotoxicity of camptothecin and 10,11-methylenedioxycamptothecin in human colon carcinoma HT-29 cells.

O'Connor PM, Nieves-Neira W, Kerrigan D, Bertrand R, Goldman J, Kohn KW, Pommier Y. O'Connor PM, et al. Among authors: pommier y. Cancer Commun. 1991 Aug;3(8):233-40. doi: 10.3727/095535491820873083. Cancer Commun. 1991. PMID: 1653585

4

Differential induction of secondary DNA fragmentation by topoisomerase II inhibitors in human tumor cell lines with amplified c-myc expression.

Bertrand R, Sarang M, Jenkin J, Kerrigan D, Pommier Y. Bertrand R, et al. Among authors: pommier y. Cancer Res. 1991 Dec 1;51(23 Pt 1):6280-5. Cancer Res. 1991. PMID: 1933888

5

10,11-Methylenedioxycamptothecin, a topoisomerase I inhibitor of increased potency: DNA damage and correlation to cytotoxicity in human colon carcinoma (HT-29) cells.

O'Connor PM, Kerrigan D, Bertrand R, Kohn KW, Pommier Y. O'Connor PM, et al. Among authors: pommier y. Cancer Commun. 1990;2(12):395-400. doi: 10.3727/095535490820873912. Cancer Commun. 1990. PMID: 2176090

6

DNA strand breaks produced by etoposide (VP-16,213) in sensitive and resistant human breast tumor cells: implications for the mechanism of action.

Sinha BK, Haim N, Dusre L, Kerrigan D, Pommier Y. Sinha BK, et al. Among authors: pommier y. Cancer Res. 1988 Sep 15;48(18):5096-100. Cancer Res. 1988. PMID: 2842045

7

Cellular pharmacology of azatoxins (topoisomerase-II and tubulin inhibitors) in P-glycoprotein-positive and -negative cell lines.

Eymin B, Solary E, Chevillard S, Dubrez L, Goldwasser F, Duchamp O, Genne P, Leteurtre F, Pommier Y. Eymin B, et al. Among authors: pommier y. Int J Cancer. 1995 Oct 9;63(2):268-75. doi: 10.1002/ijc.2910630221. Int J Cancer. 1995. PMID: 7591216

8

Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen.

Goldwasser F, Bae I, Valenti M, Torres K, Pommier Y. Goldwasser F, et al. Among authors: pommier y. Cancer Res. 1995 May 15;55(10):2116-21. Cancer Res. 1995. PMID: 7743511

9

Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin.

Fujimori A, Harker WG, Kohlhagen G, Hoki Y, Pommier Y. Fujimori A, et al. Among authors: pommier y. Cancer Res. 1995 Mar 15;55(6):1339-46. Cancer Res. 1995. PMID: 7882333

10

Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials.

Tanizawa A, Fujimori A, Fujimori Y, Pommier Y. Tanizawa A, et al. Among authors: pommier y. J Natl Cancer Inst. 1994 Jun 1;86(11):836-42. doi: 10.1093/jnci/86.11.836. J Natl Cancer Inst. 1994. PMID: 8182764

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

843 results

Search Page

Filters